A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

BACKGROUND: Prognosis of patients with glioblastoma multiforme (GBM) remains dismal, with median overall survival (OS) of about 15 months. It is therefore crucial to search alternative strategies that improve these results obtained with conventional treatments. In this context, immunotherapy seems t...

Descripción completa

Detalles Bibliográficos
Autores principales: Inogés, Susana, Tejada, Sonia, de Cerio, Ascensión López-Díaz, Pérez-Larraya, Jaime Gállego, Espinós, Jaime, Idoate, Miguel Angel, Domínguez, Pablo Daniel, de Eulate, Reyes García, Aristu, Javier, Bendandi, Maurizio, Pastor, Fernando, Alonso, Marta, Andreu, Enrique, Cardoso, Felipe Prósper, Valle, Ricardo Díez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427614/
https://www.ncbi.nlm.nih.gov/pubmed/28499389
http://dx.doi.org/10.1186/s12967-017-1202-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427614/
https://www.ncbi.nlm.nih.gov/pubmed/28499389
http://dx.doi.org/10.1186/s12967-017-1202-z

Ejemplares similares